Rhupus Syndrome and Efficacy of Etanercept Treatment

Completed

• Conditions: Rhupus Syndrome, Etanercept
• Interventions: Drug: etanercept

• Registration Number: NCT02766439
• Lead Sponsor: Yang Beibei

Brief Summary

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Detailed Description

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) \>5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Study Timeline

• Study Start: 2013-03
• Primary Completion: 2014-03
• Study Completion: 2015-03
• Status Verified: 2016-05
• Study First Submitted: 2016-05-06
• Study First Submitted QC: 2016-05-06
• Last Update Submitted: 2016-05-06
• Study First Posted: 2016-05-09
• Last Update Posted: 2016-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1

Read More

Exclusion Criteria

• those who had participated in other studies

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Rhupus syndrome, SLE without RA	etanercept	Rhupus syndrome, SLE without RA

Primary Outcome Measures

Name	Time	Method
Disease Activity Score in 28 Joints (DAS28)	24 week